Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

Assessment and modelling of antibacterial combination regimens

(2018) G.G. Rao et al.   CLINICAL MICROBIOLOGY AND INFECTION

Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam

(2017) Marc Xipell et al.   Future Microbiology

Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa

(2017) Aurélien Dinh et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa

(2017) Marguerite L Monogue et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients

(2017) Richa Gupta et al.   Journal of Global Antimicrobial Resistance

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

(2016) Matthew E. Falagas et al.   Expert Review of Anti-Infective Therapy

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration

(2016) Joseph L. Kuti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes

(2016) Christina A. Sutherland et al.   JOURNAL OF CHROMATOGRAPHIC SCIENCE

In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates

(2016) Christina A. Sutherland et al.   Annals of Clinical Microbiology and Antimicrobials

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

(2015) Roger L. Nation et al.   CLINICAL INFECTIOUS DISEASES

Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals

(2015) Christina A. Sutherland et al.   CLINICAL THERAPEUTICS

The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments

(2015) Mahableshwar S. Albur et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the CeftolozaneIn VivoPharmacokinetic/Pharmacodynamic Target

(2014) A. J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials

(2014) Abrar K Thabit et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)

(2014) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Combination therapy for carbapenem-resistant Gram-negative bacteria

(2014) M. Paul et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

(2014) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model

(2014) G. L. Drusano et al.   JOURNAL OF INFECTIOUS DISEASES

In VitroPharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

(2013) Mao Hagihara et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Meropenem in Combination with Tobramycin in a Murine Model of Pseudomonas aeruginosa Pneumonia

(2013) Arnold Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa

(2011) G. L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoComparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES